Cargando…
Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427698/ https://www.ncbi.nlm.nih.gov/pubmed/37438556 http://dx.doi.org/10.1007/s12325-023-02593-z |
| _version_ | 1785090298913751040 |
|---|---|
| author | Ornstein, Moshe C. Wood, Laura S. |
| author_facet | Ornstein, Moshe C. Wood, Laura S. |
| author_sort | Ornstein, Moshe C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10427698 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104276982023-08-17 Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor Ornstein, Moshe C. Wood, Laura S. Adv Ther Correction Springer Healthcare 2023-07-13 2023 /pmc/articles/PMC10427698/ /pubmed/37438556 http://dx.doi.org/10.1007/s12325-023-02593-z Text en © Springer Healthcare Ltd., part of Springer Nature 2023 https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Ornstein, Moshe C. Wood, Laura S. Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor |
| title | Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor |
| title_full | Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor |
| title_fullStr | Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor |
| title_full_unstemmed | Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor |
| title_short | Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor |
| title_sort | correction to: podcast to discuss therapy management for patients with metastatic renal cell carcinoma receiving first-line axitinib plus an immune checkpoint inhibitor |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427698/ https://www.ncbi.nlm.nih.gov/pubmed/37438556 http://dx.doi.org/10.1007/s12325-023-02593-z |
| work_keys_str_mv | AT ornsteinmoshec correctiontopodcasttodiscusstherapymanagementforpatientswithmetastaticrenalcellcarcinomareceivingfirstlineaxitinibplusanimmunecheckpointinhibitor AT woodlauras correctiontopodcasttodiscusstherapymanagementforpatientswithmetastaticrenalcellcarcinomareceivingfirstlineaxitinibplusanimmunecheckpointinhibitor |